Cargando…
Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cell...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845949/ https://www.ncbi.nlm.nih.gov/pubmed/36685601 http://dx.doi.org/10.3389/fimmu.2022.1081047 |
_version_ | 1784871036718678016 |
---|---|
author | Nogimori, Takuto Suzuki, Koichiro Masuta, Yuji Washizaki, Ayaka Yagoto, Mika Ikeda, Mami Katayama, Yuki Kanda, Hidenori Takada, Minoru Minami, Shohei Kobayashi, Takeshi Takahama, Shokichi Yoshioka, Yasuo Yamamoto, Takuya |
author_facet | Nogimori, Takuto Suzuki, Koichiro Masuta, Yuji Washizaki, Ayaka Yagoto, Mika Ikeda, Mami Katayama, Yuki Kanda, Hidenori Takada, Minoru Minami, Shohei Kobayashi, Takeshi Takahama, Shokichi Yoshioka, Yasuo Yamamoto, Takuya |
author_sort | Nogimori, Takuto |
collection | PubMed |
description | Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8(+) T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8(+) T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants. |
format | Online Article Text |
id | pubmed-9845949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98459492023-01-19 Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination Nogimori, Takuto Suzuki, Koichiro Masuta, Yuji Washizaki, Ayaka Yagoto, Mika Ikeda, Mami Katayama, Yuki Kanda, Hidenori Takada, Minoru Minami, Shohei Kobayashi, Takeshi Takahama, Shokichi Yoshioka, Yasuo Yamamoto, Takuya Front Immunol Immunology Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8(+) T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8(+) T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9845949/ /pubmed/36685601 http://dx.doi.org/10.3389/fimmu.2022.1081047 Text en Copyright © 2023 Nogimori, Suzuki, Masuta, Washizaki, Yagoto, Ikeda, Katayama, Kanda, Takada, Minami, Kobayashi, Takahama, Yoshioka and Yamamoto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Nogimori, Takuto Suzuki, Koichiro Masuta, Yuji Washizaki, Ayaka Yagoto, Mika Ikeda, Mami Katayama, Yuki Kanda, Hidenori Takada, Minoru Minami, Shohei Kobayashi, Takeshi Takahama, Shokichi Yoshioka, Yasuo Yamamoto, Takuya Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination |
title | Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination |
title_full | Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination |
title_fullStr | Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination |
title_full_unstemmed | Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination |
title_short | Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination |
title_sort | functional changes in cytotoxic cd8+ t-cell cross-reactivity against the sars-cov-2 omicron variant after mrna vaccination |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845949/ https://www.ncbi.nlm.nih.gov/pubmed/36685601 http://dx.doi.org/10.3389/fimmu.2022.1081047 |
work_keys_str_mv | AT nogimoritakuto functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT suzukikoichiro functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT masutayuji functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT washizakiayaka functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT yagotomika functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT ikedamami functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT katayamayuki functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT kandahidenori functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT takadaminoru functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT minamishohei functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT kobayashitakeshi functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT takahamashokichi functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT yoshiokayasuo functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination AT yamamototakuya functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination |